Drug Profile
NP 001 - UbiVac
Alternative Names: NP-001 - UbiVacLatest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator UbiVac
- Class Immunotherapies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Human papillomavirus infections
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 24 Aug 2023 Discontinued - Preclinical for Human papillomavirus infections in USA (Parenteral)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)